Nucleic acid construct and application thereof
By introducing the CcdB-ColEⅠ sequence and specific recombinase recognition sequence into the nucleic acid construct, the correct recombinant products are screened using CcdB toxic proteins, and the one-step integration of exogenous genes in the genome is achieved, solving the cumbersome and time-consuming problems in traditional methods. Improve integration efficiency and avoid the appearance of false positive colonies.
Patent Information
- Application Number
- CN202310605206.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, the genome integration process is cumbersome and time-consuming, especially through the traditional plasmid construction process, "PCR amplification fragments → product recycling → fragment recombination → transformation → screening → extraction of plasmids", which is not conducive to improving experimental efficiency and there are false positive colonies. The problem.
A nucleic acid construct is provided, including the CcdB-ColEⅠ sequence and a specific recombinase recognition sequence, and the correct recombinant product is screened using CcdB toxic proteins to avoid additional screening steps, and the one-step integration of exogenous genes into the host genome is achieved through serine recombinase.
Efficient and time-saving genome integration is achieved, with an integration efficiency of up to 86.95%, avoiding the emergence of false positive colonies and simplifying the experimental steps.
Smart Images

Figure BDA0004250360310000131 
Figure BDA0004250360310000141 
Figure BDA0004250360310000151
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a nucleic acid construct and use thereof. Background Art
[0002] As an important tool in basic and applied biological research, genome integration requires the precise and stable insertion of functional DNA fragments into the genome of the host organism. Compared with constructing the target gene on a plasmid for storage, integrating heterologous genes into a specific location in the E. coli genome for storage can effectively reduce the metabolic burden of the host organism and provide genetic stability. The resulting recombinant strain is more convenient and stable to use as a biological tool in scientific research.
[0003] With the development of synthetic biology, phage integrase recombination systems have been widely studied and used as tools for gene editing. Phage integrases are enzymes that mediate unidirectional site-specific recombination between two DNA recognition sequences (phage attachment site attP and bacterial attachment site attB). Based on their catalytic mode, integrases can be divided into two main families, namely tyrosine recombinases and serine recombinases. Tyrosine family integrases such as λ integrase use catalytic tyrosine to mediate chain cutting, tend to recognize longer attP sequences, and require other proteins encoded by phage or host bacteria. Phage integrases of the serine family are larger, use catalytic serine for chain cutting, recognize shorter attP sequences, and do not require host cofactors. Serine integrases achieve site-specific gene recombination by catalyzing the precise rearrangement of their specific recognition DNA sequences (attB and attP). This principle is used to achieve genomic integration of exogenous genes, which requires that the specific location of the genome and the plasmid where the exogenous gene is located contain the recognition sequence of the integrase at the same time. Therefore, a vector plasmid is needed with the required integrase recognition sequence, and the exogenous gene is inserted into it. The final constructed plasmid containing the exogenous gene can complete its integration into the genome under the action of serine integrase.
[0004] According to the traditional process of constructing plasmids, "PCR amplification fragments → product recovery → fragment recombination → transformation → screening → plasmid extraction", the correct plasmid obtained by screening is then used for subsequent integration. This method is not only time-consuming, but also has cumbersome experimental steps and complex operations, which is not conducive to improving experimental efficiency. Therefore, there is currently a lack of efficient and time-saving methods for constructing fusion plasmids and achieving their integration into the genome.
[0005] CcdB is a gene located on the F plasmid of E. coli that can express a toxic protein, a DNA gyrase inhibitor, which locks the DNA gyrase and broken double-stranded DNA complex, ultimately leading to cell death. Currently, this system has been used in "Gateway Cloning". On the screening plate, the presence of an empty vector plasmid without the target gene inserted is the cause of the appearance of false positive colonies. Summary of the invention
[0006] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a nucleic acid construct and use thereof.
[0007] One of the objects of the present invention is to provide a nucleic acid construct comprising a CcdB-ColEⅠ sequence, and further comprising an attB sequence or attP sequence of a first site-specific recombinase, an attB sequence or attP sequence of a second site-specific recombinase, and an attB sequence and attP sequence of a third site-specific recombinase.
[0008] Preferably, the CcdB-ColEⅠ sequence is selected from 5 ’ End to 3 ’ The two ends contain CcdB and ColEⅠ sequences respectively.
[0009] Preferably, homology arms for homologous recombination are provided at both ends of the CcdB-ColEⅠ sequence.
[0010] More preferably, the CcdB sequence includes the sequence shown as SEQ ID NO.7.
[0011] More preferably, the ColEⅠ sequence includes the sequence shown as SEQ ID NO.8.
[0012] Preferably, the site-specific recombinase is selected from serine recombinase.
[0013] More preferably, the serine recombinase is selected from one or more of TP901-1, Bxb1 and PhiC31.
[0014] Further preferably, the recognition sequence of TP901-1 is selected from attP 1 sequence and attB 1 sequence, the recognition sequence of Bxb1 is selected from attP 2 sequence and attB 2 sequence, and the recognition sequence of PhiC31 is selected from attP 3 sequence and attB 3 sequence.
[0015] More preferably, the attB 1 sequence includes the sequence shown in SEQ ID NO.1.
[0016] More preferably, the attB 2 sequence includes the sequence shown in SEQ ID NO.2.
[0017] More preferably, the attB 3 sequence includes the sequence shown in SEQ ID NO.3.
[0018] More preferably, the attP 1 sequence includes the sequence shown as SEQ ID NO.4.
[0019] More preferably, the attP 2 sequence includes the sequence shown in SEQ ID NO.5.
[0020] More preferably, the attP 3 sequence includes the sequence shown in SEQ ID NO.6.
[0021] Preferably, the attP sequence of the first site-specific recombinase and the attP sequence of the third site-specific recombinase are each independently selected from attP 1 sequence, attP 2 sequence, and attP 3 sequence.
[0022] Preferably, the attB sequence of the second site-specific recombinase and the attB sequence of the third site-specific recombinase are each independently selected from attB 1 sequence, attB 2 sequence, and attB 3 sequence.
[0023] Preferably, the nucleic acid construct contains, in sequence, an attB sequence or attP sequence of a first site-specific recombinase, a CcdB-ColEⅠ sequence, an attB sequence or attP sequence of a second site-specific recombinase, and an attB sequence and attP sequence of a third site-specific recombinase, wherein the first site-specific recombinase and the second site-specific recombinase cannot be attB sequences or attP sequences at the same time.
[0024] More preferably, the nucleic acid construct contains attP 1 sequence, CcdB-ColEⅠ sequence, attB 3 sequence, attP 2 sequence, selection marker gene and attB 2 sequence in sequence.
[0025] More preferably, the nucleic acid construct contains attP 3 sequence, CcdB-ColEⅠ sequence, attB 1 sequence, attP 2 sequence, selection marker gene and attB 2 sequence in sequence.
[0026] Preferably, the selection marker gene of the nucleic acid construct is located between the attB sequence and the attP sequence of the third site-specific recombinase.
[0027] More preferably, the selection marker is a resistance gene.
[0028] Preferably, the nucleic acid construct is an expression vector, and the CcdB-ColEⅠ sequence, the attB sequence or attP sequence of the first site-specific recombinase, the attB sequence or attP sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase are located in the expression frame of the expression vector.
[0029] More preferably, the backbone of the nucleic acid construct is selected from pKD4.
[0030] More preferably, the sequence of the nucleic acid construct is as shown in SEQ ID NO.9 or as shown in SEQ ID NO.10.
[0031] A second object of the present invention is to provide a recombination system, which comprises a vector plasmid, a plasmid expressing a first site-specific recombinase and / or a plasmid expressing a second site-specific recombinase, and a plasmid expressing a third site-specific recombinase, wherein the vector plasmid is a nucleic acid construct as described above.
[0032] Preferably, the recombination system further comprises a donor plasmid, wherein the donor plasmid comprises the target gene.
[0033] Preferably, the recombination system contains at least two different vector plasmids to facilitate the circular integration of foreign genes in the genome.
[0034] The third object of the present invention is to provide a recombinant cell obtained by introducing a recombinant vector carrying a target gene and a plasmid for specific recombination of an expression site into a host cell, wherein the recombinant vector carrying the target gene is obtained by recombination of the vector plasmid and the target gene in the recombination system described above.
[0035] A fourth object of the present invention is to provide the use of the nucleic acid construct as described above or the recombination system as described above for genome integration, gene recombination or gene editing.
[0036] A fifth object of the present invention is to provide a method for genome integration or gene recombination or gene editing, in which the target gene is recombined with the nucleic acid construct as described above to obtain a recombinant vector, and genome integration or gene recombination or gene editing is performed under the action of a site-specific recombinase.
[0037] Preferably, the method comprises the following steps:
[0038] 1) Recombining the target gene with the nucleic acid construct as described above to obtain a recombinant vector;
[0039] 2) transferring the recombinant vector and the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase into the host cell to complete genome recombination;
[0040] 3) The plasmid expressing the three-site specific recombinase is transferred into the host cell to remove the exogenous resistance.
[0041] More preferably, the method further comprises:
[0042] 4) Cyclic steps 1) to 3) are used to recombine multiple target genes into the host cell genome respectively, wherein the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase is used alternately in each cycle.
[0043] Preferably, the site-specific recombinase is selected from serine recombinase.
[0044] More preferably, the serine recombinase is selected from one or more of TP901-1, Bxb1 and PhiC31.
[0045] Compared with the prior art, the present invention has the following beneficial effects:
[0046] The present invention provides a nucleic acid construct comprising a CcdB-ColEⅠ sequence, and an exogenous target gene is integrated into the nucleic acid construct. Under the action of a site-specific recombinase, the exogenous target gene can be integrated into the host genome in one step, thereby avoiding cumbersome screening steps and saving time; and the system provided by the present invention can realize cyclic integration of the exogenous target gene, with an integration effect of more than 86.95%. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 The diagram shows the vector plasmids pYF23 and pYF24 containing the serine recombinase site in Example 1 of the present application, wherein ori represents ColEⅠ.
[0048] Figure 2 Shown are maps of the three serine recombinase expression plasmids pKD46-TP901-1, pKD46-Bxb1, and pKD46-PhiC31 in Example 3 of the present application.
[0049] Figure 3 It is a schematic diagram of agarose gel electrophoresis after the attB (TP901-1) site is introduced into the genome of Escherichia coli MG1655 in Example 4 of the present application.
[0050] Figure 4 It is a schematic diagram of agarose gel electrophoresis after picking monoclonal colonies on the plate three times and verifying them by colony PCR in Example 5 of the present application.
[0051] Figure 5 This shows the efficiency of integrating exogenous genes into the genome in Example 5 of the present application.
[0052] Figure 6 Shown are schematic diagrams of conventional methods and the methods of this application. DETAILED DESCRIPTION
[0053] The first aspect of the present invention protects a nucleic acid construct comprising a CcdB-ColEⅠ sequence, and further comprising an attB sequence or attP sequence of a first site-specific recombinase, an attB sequence or attP sequence of a second site-specific recombinase, and an attB sequence and attP sequence of a third site-specific recombinase.
[0054] The nucleic acid construct of the present application contains recognition sequences (attB sequences and / or attP sequences) of multiple specific recombinases, which provide conditions for the subsequent integration of exogenous target genes into the genome; the toxic protein gene CcdB contained in the nucleic acid construct can screen out the correct recombinant product. If CcdB can be expressed after transformation, the host cell cannot reproduce. Only the correct recombinant plasmid obtained after the CcdB gene is replaced by the exogenous target gene fragment can reproduce normally in the host cell; ColEⅠ contained in the nucleic acid construct serves as a replication initiation site, which can help the correctly recombined nucleic acid construct to amplify and reproduce in the host cell. Therefore, the nucleic acid construct of the present application can avoid the existence of colonies containing empty vector plasmids after transformation through the CcdB toxic protein gene, and no additional screening process is required. The recombinant product can be directly transformed into Escherichia coli containing serine integrase and integration sites, thereby achieving a one-step transformation.
[0055] The term "nucleic acid construct" refers to an artificially constructed nucleic acid segment that can be introduced into target cells or tissues. The nucleic acid construct includes a vector backbone, namely an expression vector and an expression cassette. The nucleic acid construct can be a plasmid.
[0056] In the nucleic acid construct of the present invention, the CcdB-ColEⅠ sequence is ’ End to 3 ’ The ends contain CcdB and ColEⅠ in sequence. The CcdB gene is located on the F plasmid of Escherichia coli and is part of the toxicity-antitoxicity system encoded by the ccd operon, ensuring that the F plasmid still exists after the cell containing the F plasmid divides (the cell containing the F plasmid can survive after the division). The toxic protein CcdB encoded by CcdB, as a DNA gyrase inhibitor, locks the DNA gyrase and the broken double-stranded DNA complex, making the DNA gyrase unable to function, and ultimately leading to cell death. The nucleic acid construct of the present invention contains the CcdB gene. When the CcdB gene is expressed, the nucleic acid construct cannot reproduce after being transformed into a host cell; after successful cloning, the inserted fragment completely replaces the CcdB gene, and the colony without the inserted fragment cannot grow and reproduce, so the correct clone can be efficiently identified, avoiding cumbersome screening steps and saving time.
[0057] In the nucleic acid construct of the present invention, the nucleic acid construct sequentially contains the attB sequence or attP sequence of the first site-specific recombinase, the CcdB-ColEⅠ sequence, the attB sequence or attP sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase, wherein the first site-specific recombinase and the second site-specific recombinase cannot be attB sequences or attP sequences at the same time. For example, in a certain embodiment, the nucleic acid construct sequentially contains the attP sequence of the first site-specific recombinase, the CcdB-ColEⅠ sequence, the attB sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase; in another embodiment, the nucleic acid construct sequentially contains the attB sequence of the first site-specific recombinase, the CcdB-ColEⅠ sequence, the attP sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase.
[0058] In the nucleic acid construct of the present invention, the site-specific recombinase is selected from serine recombinase. Preferably, the serine recombinase is selected from one or more of TP901-1, Bxb1 and PhiC31. The recognition sequence of TP901-1 is selected from attP1 sequence and attB 1 sequence, the recognition sequence of Bxb1 is selected from attP 2 sequence and attB 2 sequence, and the recognition sequence of PhiC31 is selected from attP 3 sequence and attB 3 sequence.
[0059] In the nucleic acid construct of the present invention, the attP sequence of the first site-specific recombinase and the attP sequence of the third site-specific recombinase are each independently selected from attP 1 sequence, attP 2 sequence, and attP 3 sequence; the attB sequence of the second site-specific recombinase and the attB sequence of the third site-specific recombinase are each independently selected from attB1 sequence, attB 2 sequence, and attB 3 sequence.
[0060] In the nucleic acid construct of the present invention, the nucleic acid construct further comprises a screening marker gene, which is located between the attB sequence and the attP sequence of the third site-specific recombinase. The screening marker is a resistance gene, which is KanR and / or NeoR.
[0061] attB 1 sequence includes the sequence shown in SEQ ID NO.1
[0062] atgccaacacaattaacatctcaatcaaggtaaatgctttttgctttttttgc(SEQ ID NO.1)
[0063] attB 2 sequences include the sequence shown in SEQ ID NO.2
[0064] tcggccggcttgtcgacgacggcggtctccgtcgtcaggatcatccgggc(SEQ ID NO.2)
[0065] attB 3 sequences include the sequence shown in SEQ ID NO.3
[0066] tgcgggtgccagggcgtgcccttgggctccccgggcgcgtactcc(SEQ ID NO.3)
[0067] attP 1 sequence includes the sequence shown in SEQ ID NO.4
[0068] gcgagtttttatttcgtttatttcaattaaggtaactaaaaaactccttt(SEQ ID NO.4)
[0069] attP 2 sequences include the sequence shown in SEQ ID NO.5
[0070] gtcgtggtttgtctggtcaaccaccgcggtctcagtggtgtacggtacaaaccccgac(SEQ IDNO.5)
[0071] attP 3 sequences include the sequence shown in SEQ ID NO.6
[0072] gtgccccaactggggtaacctttgagttctctcagttggggg(SEQ ID NO.6)
[0073] The CcdB sequence includes the sequence shown in SEQ ID NO.7
[0074] atgcagtttaaggtttacacctataaaagagagagccgttatcgtctgtttgtggatgtacagagtgatattattgacacgcccgggcgacggatggtgatccccctggccagtgcacgtctgctgtcagataaagtctcccgtgaactttacccggtggtgcatatcggggatgaaagctggcgcatgatgaccaccgatatggccagtgtgccggtctccgttatcggggaagaagtggctgatctcagccaccgcgaaaatgacatcaaaaacgccattaacctgatgttctggggaatataa(SEQ ID NO.7)
[0075] The ColEⅠ sequence includes the sequence shown in SEQ ID NO.8
[0076] tttccacaggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaa(SEQ IDNO.8)
[0077] In certain specific embodiments, the nucleic acid construct is
[0078] It contains attP 1 sequence, CcdB-ColEⅠ sequence, attB 3 sequence, attP 2 sequence, screening marker gene and attB 2 sequence; it may also contain attP 1 sequence, CcdB-ColEⅠ sequence, attB 2 sequence, attP 3 sequence, screening marker gene and attB 3 sequence; it may also contain attP 2 sequence, CcdB-ColEⅠ sequence, attB 1 sequence, attP 3 sequence, screening marker gene and attB 3 sequence; it may also contain attP 2 sequence, CcdB-ColEⅠ sequence, attB 3 sequence, attP 1 sequence, screening marker gene and attB 1 sequence; it may also contain attP 3 sequence, CcdB-ColEⅠ sequence, attB 1 sequence, attP 2 sequence, screening marker gene and attB 2 sequence; it may also contain attP 3 sequence, CcdB-ColEⅠ sequence, attB2 sequence, attP 1 sequence, screening marker gene and attB 1 sequence.
[0079] In the nucleic acid construct of the present invention, homology arms for homologous recombination are provided at both ends of the CcdB-ColEⅠ sequence.
[0080] In the nucleic acid construct of the present invention, the nucleic acid construct is an expression vector, and the CcdB-ColEⅠ sequence, the attB sequence or attP sequence of the first site-specific recombinase, the attB sequence or attP sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase are located in the expression framework of the expression vector. For example, the backbone of the expression vector is selected from pKD4.
[0081] In the nucleic acid construct of the present invention, the sequence of the nucleic acid construct is shown in SEQ ID NO.9 or SEQ ID NO.10. The present application uses pKD4 as the starting plasmid to construct two vector plasmids, namely, vector plasmid pYF23 and vector plasmid pYF 24. The structure of vector plasmid pYF23 is pKD4 (vector) -attP 1-CcdB-ColEⅠ-attB 3-attP2-KanR-attB 2, and the structure of vector plasmid pYF 24 is pKD4 (vector) -attP 3-CcdB-ColEⅠ-attB 1-attP2-KanR-attB2; the maps of vector plasmid pYF23 and vector plasmid pYF 24 are shown in Figure 1The sequence of the vector plasmid pYF23 is shown in SEQ ID NO.9, and the sequence of the vector plasmid pYF24 is shown in SEQ ID NO.10.
[0082] The sequence of the nucleic acid construct is shown in SEQ ID NO.9
[0083]
[0084] The sequence of the nucleic acid construct is shown in SEQ ID NO.10
[0085]
[0086] The third aspect of the present invention protects a recombination system, which comprises a vector plasmid, a plasmid expressing a first site-specific recombinase and / or a plasmid expressing a second site-specific recombinase, and a plasmid expressing a third site-specific recombinase, wherein the vector plasmid is a nucleic acid construct as described above.
[0087] In the recombination system of the present invention, the recombination system further comprises a donor plasmid, and the donor plasmid comprises a target gene.
[0088] In the recombination system described in the present invention, the recombination system contains at least two different vector plasmids to facilitate the cyclic integration of exogenous genes in the genome. In certain embodiments, the recombination system includes two different expression vectors. For the convenience of distinction, one expression vector is recorded as the first expression vector, and the other expression vector is recorded as the second expression vector. The attB sequence or attP sequence of the first site-specific recombinase in the first expression vector and the attB sequence or attP sequence of the second site-specific recombinase in the second expression vector recognize the same site-specific recombinase, and the first site-specific recombinase and the second site-specific recombinase cannot be attB sequences or attP sequences at the same time. Under the action of the specific recombinase, the first expression vector of the present application integrates the attB sequence or attP sequence of the second site-specific recombinase and the exogenous target gene into the host cell through the attB sequence or attP sequence of the first site-specific recombinase, and uses the attB sequence or attP sequence of the second site-specific recombinase as the receptor element for the next round of integration, and integrates correspondingly with the attP sequence or attB sequence of the first site-specific recombinase in the second expression vector, thereby realizing the cyclic integration of the exogenous target gene. For example,
[0089] When the recognition sequence of the second site-specific recombinase of the first expression vector is attB 1 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attP 1 sequence; or when the recognition sequence of the second site-specific recombinase of the first expression vector is attP 1 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attB 1 sequence.
[0090] When the recognition sequence of the second site-specific recombinase of the first expression vector is attB 2 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attP 2 sequence; or when the recognition sequence of the second site-specific recombinase of the first expression vector is attP 2 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attB 2 sequence.
[0091] When the recognition sequence of the second site-specific recombinase of the first expression vector is attB 3 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attP 3 sequence; or when the recognition sequence of the second site-specific recombinase of the first expression vector is attP 3 sequence, the recognition sequence of the first site-specific recombinase of the second expression vector is attB 3 sequence.
[0092] In a specific embodiment, the recombination system comprises a vector plasmid pYF23 whose sequence is shown as SEQ ID No.9 and a vector plasmid pYF24 whose sequence is shown as SEQ ID No.10.
[0093] The fourth aspect of the present invention protects a recombinant cell obtained by introducing a recombinant vector carrying a target gene and a plasmid for specific recombination of an expression site into a host cell, wherein the recombinant vector carrying the target gene is obtained by recombination of a vector plasmid and the target gene in the recombination system as described above.
[0094] In the recombinant cell of the present invention, the host cell comprises an attP sequence or attB sequence corresponding to the attB sequence or attP sequence of the first site-specific recombinase contained in the vector plasmid in the recombinant system. In a specific embodiment, when the vector plasmid comprises an attP 1 sequence and a CcdB-ColEⅠ sequence, the genome of the host cell comprises a recombination attachment site attB 1 sequence; or when the vector plasmid comprises an attB 1 sequence and a CcdB-ColEⅠ sequence, the genome of the host cell comprises a recombination attachment site attP 1 sequence. In another specific embodiment, when the vector plasmid comprises an attP 2 sequence and a CcdB-ColEⅠ sequence, the genome of the host cell comprises a recombination attachment site attB2 sequence; or when the vector plasmid comprises an attB 2 sequence and a CcdB-ColEⅠ sequence, the genome of the host cell comprises a recombination attachment site attP 2 sequence. In addition, when the vector plasmid contains attP 3 sequence and CcdB-ColEⅠ sequence, the genome of the host cell contains the recombination attachment site attB 3 sequence; when the vector plasmid contains attB 3 sequence and CcdB-ColEⅠ sequence, the genome of the host cell contains the recombination attachment site attP 3 sequence. In certain embodiments, the host cell can be a Gram-negative bacterium or a Gram-positive bacterium, preferably a Gram-negative bacterium, more preferably Escherichia coli, specifically Escherichia coli MG1655, and the CsgA gene of the Escherichia coli MG1655 is replaced with the attB 1 sequence by the λ-Red homologous recombination method.
[0095] The fifth aspect of the present invention protects the use of the nucleic acid construct as described above or the recombination system as described above for gene integration or gene recombination or gene editing.
[0096] The sixth aspect of the present invention protects a method for gene integration, gene recombination or gene editing, comprising the following steps:
[0097] 1) Recombining the target gene with the nucleic acid construct as described above to obtain a recombinant vector;
[0098] 2) transferring the recombinant vector and the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase into the host cell to complete genome recombination;
[0099] 3) Transform the plasmid expressing the three-site specific recombinase into the host cell to remove the foreign resistance;
[0100] Optionally, also include:
[0101] 4) Cyclic steps 1) to 3) are used to recombine multiple target genes into the host cell genome respectively, wherein the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase is used alternately in each cycle.
[0102] In the method of the present invention, the site-specific recombinase is selected from serine recombinase. Preferably, the serine recombinase is selected from one or more of TP901-1, Bxb1 and PhiC31.
[0103] In the method of the present invention, the method can also be used to transfer the plasmid and nucleic acid construct expressing the serine recombinase into the host cell. Taking the first site-specific recombinase, the second site-specific recombinase and the third site-specific recombinase of the nucleic acid construct as an example, respectively, TP901-1, PhiC31 and Bxb1 are used as the examples, the construction method of the plasmid expressing the serine recombinase is as follows: 1) PCR amplification is performed using pKD46 as the vector plasmid to obtain a linear product pKD46; 2) PCR amplification is performed using pET22a-TP901-1, pET22a-Bxb1 and pET22a-PhiC31 as templates to obtain a TP901-1 fragment, a Bxb1 fragment and a PhiC31 fragment; 3) the TP901-1 fragment, the Bxb1 fragment and the PhiC31 fragment are connected to the linear product pKD46 to obtain a plasmid expressing the serine recombinase TP901-1, a plasmid expressing the serine recombinase Bxb1 and a plasmid expressing the serine recombinase PhiC31, respectively.
[0104] In a specific embodiment, the method comprises the following steps:
[0105] The first round of integration: the target gene 1 is integrated into the vector plasmid pYF23, and then contacted with a plasmid expressing the serine recombinase TP901-1 and Escherichia coli containing the attB 1 sequence to integrate the target gene 1 into the genome of Escherichia coli to obtain cell line I; after the integration is completed, the genome of cell line I contains the exogenous target gene 1 and attB 3 sequence, among which the attB3 sequence serves as the integration starting point of the second round; then contacted with a plasmid expressing the serine recombinase Bxb1 to eliminate the resistance gene and ColEⅠ replicon in the vector plasmid pYF23.
[0106] The second round of integration: the target gene 2 is then integrated into the vector plasmid pYF24, which is then contacted with the cell line I expressing the serine recombinase PhiC31 to integrate the target gene 2 into the genome of the cell line I, that is, the attP 3 sequence in the vector plasmid pYF24 is recombined with the attB 3 sequence of the cell line I to connect the target gene 2 to the downstream of the target gene 1, thereby obtaining the cell line II; after the integration is completed, the genome of the cell line II contains the target gene 1, the target gene 2 and the attB 1 sequence, wherein the attB 1 sequence serves as the starting point for the third round of integration.
[0107] The third round of integration: The target gene 3 is then integrated into the vector plasmid pYF23, and then contacted with the expression of serine recombinase TP901-1 and cell line II to integrate the target gene 3 into the genome of cell line II, that is, the attP 1 sequence in the vector plasmid pYF23 is recombined with the attB 1 sequence of cell line II to connect the target gene 3 to the downstream of the target gene 2, thereby obtaining cell line III; after the integration, the genome of cell line III contains the target gene 1, target gene 2, target gene 3 and attB 1 sequence, wherein the attB 1 sequence serves as the fourth round of integration starting point…
[0108] Target gene 1, target gene 2, target gene 3, ... are the same as or different from each other.
[0109] The method of the present invention integrates the target gene on the donor element into the genome of the host cell through the action of serine integrase in a host cell containing the receptor element attB. The obtained cell line I contains a new attB sequence, which can serve as the receptor element for the next round of genome integration, thereby realizing the cyclic iterative integration of DNA fragments.
[0110] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0111] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0112] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0113] The present invention is further described below through specific examples. The present invention can be embodied through many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions, such as the conditions described in Sambrook et al. Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the reagent and instrument vendors. The reagents used, unless otherwise specified, are all commercially available or publicly available reagents.
[0114] For the pCP20 plasmid, see https: / / doi.org / 10.1016 / 0378-1119(95)00193-A.
[0115] Example 1 Construction of vector plasmid pYF23 providing exogenous integration sites
[0116] 1.1. Construction of the vector plasmid pYF23 containing CcdB-ColEⅠ
[0117] 1.1.1. Obtaining the linear products ColEⅠ and CcdB
[0118] The DNA sequence of the ColEⅠ fragment was obtained using pSB1C3 as a template. The DNA sequence of the CcdB toxic gene was synthesized by the company, and primers were designed for PCR amplification. The linear products ColEⅠ and CcdB were used for subsequent plasmid construction. The primers for amplifying the ColEⅠ and CcdB fragments are shown in Table 3. The sequence of CcdB is SEQ ID No.7, and the sequence of ColEⅠ is SEQ ID No.8.
[0119] Amplification system A is shown in Table 1. Amplification system A: Q5 High-Fidelity DNA Polymerase (New England Biolabs).
[0120] Table 1
[0121] Element Volume (μl) 5× Q5 reaction buffer 10 10mM dNTPs 1 10 μM forward primer 2.5 10 μM reverse primer 2.5 Q5 High-Fidelity DNApolymerase 0.5 Template DNA 1 <![CDATA[ddH2O]]> 32.5
[0122] The amplification program is shown in Table 2.
[0123] Table 2
[0124] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 72 30s extend 72 1min 30s 30 cycles Final extension 72 5min Final Stage 4
[0125] Table 3
[0126]
[0127] 1.1.2. Obtaining linear products attP 1, attB 2, attP 2, attB 3
[0128] The DNA sequences of attP 1, attB 2, attP 2, and attB 3 were obtained by PCR amplification using primers as templates, and the linear products were used for subsequent plasmid construction. The primers are shown in Table 6. The sequences of attP 1, attB 2, attP 2, and attB 3 are SEQ ID No. 4, SEQ ID No. 2, SEQ ID No. 5, and SEQ ID No. 3, respectively.
[0129] Amplification system B is shown in Table 4. Amplification system B (50 μl reaction system): Q5 High-Fidelity DNA Polymerase (New England Biolabs)
[0130] Table 4
[0131] Element Volume (μl) 5× Q5 reaction buffer 10 10mM dNTPs 1 10 μM forward primer 10 10 μM reverse primer 10 Q5 High-Fidelity DNA polymerase 0.5 <![CDATA[ddH2O]]> 18.5
[0132] The amplification program is shown in Table 5.
[0133] Table 5
[0134] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 72 30s extend 72 30s 10 cycles Final extension 72 5min Final Stage 4
[0135] Table 6
[0136]
[0137] 1.1.3 Linear product pKD4
[0138] Using pKD4 plasmid as the vector plasmid, primers were designed for PCR amplification to obtain the linear product pKD4 and used for the subsequent construction of the vector plasmid pYF 23. The primer sequences are shown in Table 8.
[0139] The amplification system is the same as the amplification system A in step 1.1., except that the template and primers are different.
[0140] The amplification program is shown in Table 7.
[0141] Table 7
[0142] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 66 30s extend 72 2min 30 cycles Final extension 72 5min Final Stage 4
[0143] Table 8
[0144]
[0145] 1.2 Homologous recombination
[0146] Using the "HiFi DNA Assembly Master Mix" kit from NEB, the linear products ColEⅠ and CcdB from step 1.1.1, the linear products attP 1, attB 2, attP 2, attB 3 from step 1.1.2, and the linear product pKD4 from step 1.1.3 were homologously recombined to finally obtain a vector plasmid containing a serine recombinase site.
[0147] 1.3 Sequencing
[0148] The vector plasmid containing the serine recombinase site in step 1.2 was subjected to Sanger sequencing. The sequencing result was correct, and the expected plasmid was obtained, that is, the vector plasmid pYF23 containing CcdB-ColEⅠ (referred to as vector plasmid pYF23). The map of vector plasmid pYF 23 is shown in Figure 1 .
[0149] The plasmid containing CcdB-ColEⅠ can be amplified and propagated in the E. coli strain DB3.1;
[0150] The structure of pYF23 is as follows: pKD4 (vector) -attP 1 -biofix (prefix) -CcdB -ColEⅠ -biofix (suffix) -attB 3 -attP 2 -KanR -attB 2; the sequence of the vector plasmid pYF23 is shown in SEQ ID NO. 9. As standardized elements of synthetic biology, biofix (prefix) and (suffix) are a common sequence on the plasmid, which is more convenient for subsequent cloning and recombination (without changing primers).
[0151] Among them, attB / P 1 refers to attB / P(TP901-1), attB / P 2 refers to attB / P(Bxb1), and attB / P 3 refers to attB / P(PhiC31).
[0152] At the same time, the construction method of vector plasmid pYF23 was used to construct vector plasmid pYF24. The map of vector plasmid pYF24 is shown in Figure 1 .
[0153] The structure of pYF24 is as follows: pKD4 (vector)-attP 3-biofix (prefix)-CcdB-ColEⅠ-biofix (suffix)-attB 1-attP 2-KanR-attB 2. The sequence of the vector plasmid pYF24 is shown in SEQ ID NO.10.
[0154] Example 2 Insertion of exogenous target gene into vector plasmid pYF23
[0155] In this embodiment, taking the exogenous target gene as sfGFP as an example, inserting the exogenous target gene sfGFP into the vector plasmid pYF23 obtained in Example 1 comprises the following steps:
[0156] 2.1. Construction of recombinant plasmid containing sfGFP
[0157] 2.1.1. Obtaining the linear product pYF23
[0158] Forward and reverse primers were designed for the vector plasmid pYF23 obtained in Example 1 to perform PCR amplification to obtain a linear product pYF23 and used for the subsequent construction of a recombinant plasmid containing sfGFP. The forward and reverse primers are shown in Table 10.
[0159] The amplification system is the same as the amplification system A in step 1.1.1, except that the template and primers are different.
[0160] The amplification program is shown in Table 9.
[0161] Table 9
[0162] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 72 30s extend 72 1min 30s 30 cycles Final extension 72 5min Final Stage 4
[0163] Table 10
[0164]
[0165]
[0166] 2.1.2. Obtaining the linear product sfGFP
[0167] Using the donor plasmid as a template, the exogenous target gene (sfGFP) fragment was obtained by PCR amplification, and the linear product sfGFP was obtained and used for the subsequent construction of the recombinant plasmid containing sfGFP. The primers for PCR amplification are shown in Table 12. The sequence of the donor plasmid is shown in SEQ ID NO.11.
[0168] The amplification system is the same as the amplification system A in step 1.1.1, except that the template and primers are different.
[0169] The amplification program is shown in Table 11.
[0170] Table 11
[0171] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 72 30s extend 72 1min 30 cycles Final extension 72 5min Final Stage 4
[0172] Table 12
[0173]
[0174] 2.2 Homologous recombination
[0175] Using the "HiFi DNA Assembly Master Mix" kit from NEB, the linear product pYF23 from step 2.1.1 and the linear product sfGFP from step 2.1.2 were homologously recombined to obtain a recombinant product.
[0176] Example 3 Construction of a plasmid expressing serine recombinase
[0177] In this embodiment, pKD46 is used as a starting plasmid to construct a plasmid expressing serine recombinase, including the following steps:
[0178] 3.1. Obtaining the linear product pKD46
[0179] Using pKD46 as the vector plasmid, primers were designed for PCR amplification to obtain the linear product pKD46 and used for the subsequent construction of the plasmid expressing the serine recombinase. The primers are shown in Table 14.
[0180] The amplification system is the same as the amplification system A in step 1.1.1 in Example 1, except that the template and primers are different.
[0181] The amplification program is shown in Table 13.
[0182] Table 13
[0183]
[0184]
[0185] Table 14
[0186]
[0187] 3.2. Obtaining the linearized products TP901-1, Bxb1 and PhiC31
[0188] The DNA sequences of the three serine recombinases TP901-1, Bxb1 and PhiC31 were obtained by PCR amplification using pET22a-TP901-1, pET22a-Bxb1 and pET22a-PhiC31 as templates, and the linearized products were used for the subsequent construction of the serine recombinase expression plasmids. The primers are shown in Table 15.
[0189] The amplification system is the same as the amplification system A in step 1.1.1 in Example 1, except that the template and primers are different.
[0190] Table 15
[0191]
[0192] The underlined parts are homologous sequences at both ends of the linearized product of pKD46 obtained in 3.1.
[0193] 3.3 Homologous recombination
[0194] Using the "HiFi DNA Assembly Master Mix" kit from NEB, the three fragments TP901-1, Bxb1, and PhiC31 obtained in step 3.1 were homologously recombined with the linear product pKD46 of step 3.1, and finally three plasmids containing serine recombinase expression were obtained.
[0195] 3.4 Sequencing
[0196] The inserted fragments were subjected to Sanger sequencing, and the sequencing results were correct, and the expected plasmids were obtained, namely, pKD46-TP901-1 plasmid, pKD46-Bxb1 plasmid, and pKD46-PhiC31 plasmid. The maps of the three plasmids are shown in Figure 2The sequences of the pKD46-TP901-1 plasmid, the pKD46-Bxb1 plasmid, and the pKD46-PhiC31 plasmid are the sequence shown in SEQ ID NO.12, the sequence shown in SEQ ID NO.13, and the sequence shown in SEQ ID NO.14, respectively.
[0197] Example 4 Obtaining a strain with attB 1 sequence
[0198] In this example, a pKD4 plasmid with an attB 1 sequence (the pKD4 plasmid with an attB 1 sequence is abbreviated as pKD4-attB 1 plasmid) was constructed and a strain with an attB 1 sequence was obtained, including the following:
[0199] 4.1. Construction of pKD4-attB 1 plasmid
[0200] 4.1.1. Obtaining the linearized product pKD4
[0201] Using pKD4 as the vector plasmid, PCR amplification was performed using the forward and reverse primers of the ori part and the forward and reverse primers of the resistance gene part to obtain the linearized product pKD4 for the subsequent construction of the pKD4-attB 1 plasmid. The forward and reverse primers of the ori part and the forward and reverse primers of the resistance gene part are shown in Table 17.
[0202] Amplification system A is the same as amplification system A in step 1.1.1 in Example 1, except that the primers and templates are different.
[0203] The amplification program is shown in Table 16.
[0204] Table 16
[0205] step Temperature(℃) time Pre-denaturation 98 30s transsexual 98 10s annealing 66 30s extend 72 2min 30 cycles Final extension 72 5min Final Stage 4
[0206] Table 17
[0207]
[0208] 4.1.2. Obtaining the linearized product attB 1
[0209] PCR amplification was performed using forward and reverse primers to obtain the linearized product attB 1 for subsequent plasmid construction. Forward and reverse primers are shown in Table 19.
[0210] Amplification system B is the same as amplification system B in step 1.1.2 of Example 1, except that the primers are different.
[0211] The amplification program is shown in Table 18.
[0212] Table 18
[0213]
[0214]
[0215] Table 19
[0216]
[0217] 4.1.3. Obtaining the left and right homology arms CsgA-left and CsgA-right fragments
[0218] The DNA sequences of the left and right homologous arms CsgA-left and CsgA-right fragments were amplified by PCR using the E. coli MG1655 genome as a template, and the forward and reverse primers of CsgA-left were designed to obtain the linearized product CsgA-left for the subsequent plasmid construction; the forward and reverse primers of CsgA-right were designed to obtain the linearized product CsgA-right for the subsequent plasmid construction. The primer sequences are shown in Table 22.
[0219] Amplification system C (50 μl reaction system): Green Taq mix (Vazyme), see Table 20.
[0220] Table 20
[0221] Element Volume (μl) Green Taq mix 25 10 μM forward primer 2.5 10 μM reverse primer 2.5 Template DNA 1 <![CDATA[ddH2O]]> 19
[0222] The amplification program is shown in Table 21.
[0223] Table 21
[0224] step Temperature(℃) time Pre-denaturation 95 3min transsexual 95 15s annealing 52 15s extend 72 1min 35 cycles Final extension 72 5min Final Stage 4
[0225] Table 22
[0226]
[0227] 4.2. Obtaining pKD4-attB 1 plasmid by homologous recombination
[0228] Using the "HiFi DNA Assembly Master Mix" kit from NEB, the linearized product pKD4 obtained in step 4.1.1, the linearized product attB 1 obtained in step 4.1.2, and the left and right homology arms CsgA-left and CsgA-right fragments obtained in step 4.1.3 were homologously recombined.
[0229] 4.3 Sequencing
[0230] The product after homologous recombination in step 4.2 was subjected to Sanger sequencing, and the sequencing result was correct, obtaining the pKD4-attB1 plasmid.
[0231] Herein, attB / P 1 refers to attB / P (TP901-1).
[0232] 4.4. Obtaining the linear fragment of attB1 carrying the left and right homology arms
[0233] Using the plasmid pKD4-attB 1 obtained in step 4.3 as a template, design forward and reverse primers for PCR amplification to obtain the linearized fragment of attB 1 carrying the left and right homology arms. The primer sequences are shown in Table 24.
[0234] The amplification system is the same as amplification system C in step 4.1.3, except that the template and primers are different.
[0235] The amplification program is shown in Table 23.
[0236] Table 23
[0237] step Temperature(℃) time Pre-denaturation 95 3min transsexual 95 15s annealing 55 15s extend 72 3min 30s 30 cycles Final extension 72 5min Final Stage 4
[0238] Table 24
[0239]
[0240] 4.5. Obtaining E. coli MG1655 strain with attB 1 sequence
[0241] 1) Inoculate the overnight E. coli MG1655 culture in fresh LB at a ratio of 1:100, shake at 37°C for 3-4 hours, stop culturing when OD600 reaches 0.4-0.6, and make electroporation competent cells on ice;
[0242] 2) Add 5 μL of pKD46 plasmid to the competent cells in step 4.5 1) and resuspend them. Take 70 μL of the mixed product (E. coli containing pKD46 plasmid) and transfer it to the electroporation cup for electroporation transformation;
[0243] 3) Add 1 mL of antibody-free LB to the electroporation cup to resuspend the cells, transfer to a centrifuge tube and culture at 30°C, 250 rpm for 1 hour to obtain the culture solution;
[0244] 4) Take 100 μL of the culture solution in step 4.5 (3) and apply it on an LB agar plate with ampicillin and culture it overnight at 30°C for about 16 hours;
[0245] 5) Select a single clone from the overnight plate in step 4.5, inoculate it into 5 mL of LB medium containing ampicillin, and culture it overnight at 30°C and 250 rpm to obtain a bacterial liquid. The LB medium contains 100 μg / mL ampicillin.
[0246] 6) Inoculate the bacterial solution in step 4.5 5) into new LB medium at a ratio of 1:100, shake at 37°C for 3-4h, stop culturing when OD600 reaches 0.4-0.6, and make electroporation competent cells on ice. According to the above process, electroporate 5 μL of the linear fragment attB 1 obtained in step 4.4 into the E. coli containing the pKD46 plasmid obtained in step 4.5 2), and culture at 37°C overnight for about 16h after plating;
[0247] 7) Select 5 monoclonal colonies from the overnight LB agar plate in step 4.5 6), design primers for colony PCR, and send the PCR product with the target band to test to obtain Escherichia coli MG1655 in which CsgA is replaced by attB 1 and the genome carries kanamycin resistance, which is recorded as attB 1-ΔCsgA MG1655; the primers are shown in Table 27.
[0248] Here, the colony PCR system (50 μl reaction system): Green Taq mix (Vazyme), see Table 25.
[0249] Table 25
[0250] Element Volume (μl) Green Taq mix 25 10 μM forward primer 2.5 10 μM reverse primer 2.5 Bacterial liquid 1 <![CDATA[ddH2O]]> 19
[0251] Amplification program Table 26.
[0252] Table 26
[0253] step Temperature(℃) time Pre-denaturation 95 3min transsexual 95 15s annealing 55 15s extend 72 3min 30s 30 cycles Final extension 72 5min Final Stage 4
[0254] Table 27
[0255]
[0256] 8) Prepare the attB 1-ΔCsgA MG1655 strain obtained in step 4.5 7) into an electroporation competent state, transfer the pCP20 plasmid into it according to the above electroporation method, and plate on an agar plate at 30°C overnight;
[0257] 9) Pick a single clone from the agar plate in step 4.5 (8) and incubate overnight in 5 mL of ampicillin-resistant LB; the next day, streak on an ampicillin LB agar plate and incubate overnight at 30°C;
[0258] 10) Select 9 monoclonal colonies from the agar plate in step 4.5 9), dissolve them in 10 μL of non-resistant LB, use a pipette tip to drop 1 μL of bacterial solution on the plates with kanamycin and ampicillin, and let the bacterial solution dry overnight at 30°C; finally, select the colonies that grow on the ampicillin plate but not on the kanamycin plate, inoculate them in 5 mL of non-resistant LB, and culture them overnight at 37°C and 250 rpm to obtain the non-resistant attB 1-ΔCsgA MG1655 final strain. Among them, the LB medium contains 100 μg / mL ampicillin and 50 μg / mL kanamycin; among them, to make the electrotransformation competent state, the bacterial solution needs to be divided into 1.5 mL centrifuge tubes, centrifuged and discarded the supernatant, and washed 4 times with sterile water, and finally resuspended with 70 μL sterile water.
[0259] The sequence of the pKD4-attB (TP901-1) plasmid is the sequence shown in SEQ ID NO.15.
[0260] Figure 3 Schematic diagram of agarose gel electrophoresis after the attB 1 sequence was introduced into the genome of Escherichia coli MG1655.
[0261] from Figure 3 It can be seen that the PCR results of the five selected colonies all have the target bands, indicating that the attB 1 sequence was successfully inserted into the genome of Escherichia coli MG1655.
[0262] Example 5 Integration of foreign genes into the genome of Escherichia coli MG1655
[0263] Using the plasmid expressing the serine recombinase of Example 3, the recombinant product obtained in step 2.2 of Example 2 and the Escherichia coli MG1655 with the attB 1 sequence obtained in step 4.5 of Example 4 (abbreviated as attB 1-ΔCsgAMG1655 strain) were co-cultured to integrate sfGFP into the MG1655 Escherichia coli genome, including the following:
[0264] 5.1. Obtaining attB 1-ΔCsgA MG1655 strain containing pKD46-TP901-1 plasmid
[0265] 1) inoculating the attB 1-ΔCsgA MG1655 strain obtained in Example 4 into 5 mL of antibiotic-free LB, culturing at 37° C. and 250 rpm, stopping when OD600 reached 0.4-0.6, and making electroporation competent cells on ice;
[0266] 2) Add 2.5 μL of the pKD46-TP901-1 plasmid obtained in Example 3 to the competent cells, mix well, and take 70 μL of the resuspended cells into an electroporation cuvette for electroporation transformation;
[0267] 3) Add 1 mL of antibody-free LB to the electroporation cup to resuspend the cells, transfer to a centrifuge tube and culture at 30°C, 250 rpm for 1 hour to obtain the culture solution;
[0268] 4) Apply 100 μL of culture solution on LB agar plate with ampicillin and culture overnight at 30°C for about 16 hours;
[0269] 5) The single colony on the plate is the attB 1-ΔCsgA MG1655 strain containing the pKD46-TP901-1 plasmid.
[0270] 5.2. Preparation of chemically competent cells
[0271] 1) Inoculate the attB 1-ΔCsgA MG1655 strain containing the pKD46-TP901-1 plasmid from step 5.1 into 5 mL of ampicillin-resistant LB and add 0.1 M L-arabinose for induction. Cultivate at 30°C, 250 rpm, and culture for 6-8 h.
[0272] 2) Stop when OD600 reaches 0.4-0.6, place the bacterial solution on ice for 10 minutes, divide the bacteria into 1.5 mL centrifuge tubes, and centrifuge at 4°C, 12,000 × g for 1 min in a low-temperature centrifuge;
[0273] 3) Discard the supernatant, wash three times with 500 μL ddH2O pre-cooled on ice, and centrifuge at 4°C, 12,000 × g for 1 min;
[0274] 4) Aspirate the supernatant, add 0.1 M CaCl2 to resuspend the cells, and incubate on ice for 30 min; then centrifuge at 4°C, 5000×g for 10 min;
[0275] 5) Discard the supernatant, add 100 μL of pre-cooled 0.1 M CaCl2 solution containing 10% glycerol solution, and gently resuspend the bacteria to obtain chemically competent cells.
[0276] 5.3 Chemical transformation
[0277] The recombinant plasmid obtained in step 2.2 of Example 2 was chemically transformed into the chemically competent cells in step 5.2, and 100 μL of the bacterial solution was applied to an LB agar plate with kanamycin resistance at 37°C overnight;
[0278] Pick several monoclonal colonies on the LB agar plate, design appropriate primers for PCR verification, and finally verify whether it is a positive integration result by agarose gel electrophoresis. The primer sequences are shown in Table 30.
[0279] Here, the colony PCR system (50 μl reaction system): Green Taq mix (Vazyme), see Table 28.
[0280] Table 28
[0281] Element Volume (μl) Green Taq mix 25 10 μM forward primer 2.5 10 μM reverse primer 2.5 Bacterial liquid 1 <![CDATA[ddH2O]]> 19
[0282] The amplification program is shown in Table 29.
[0283] Table 29
[0284] step Temperature(℃) time Pre-denaturation 95 3min transsexual 95 15s annealing 52 15s extend 72 2min 30 cycles Final extension 72 5min Final Stage 4
[0285] Table 30
[0286]
[0287] 5.5. Elimination of resistance and replication origins carried by exogenous genes integrated into the genome
[0288] 1) Inoculate the correct single colony obtained in step 5.4 into 5 mL of antibiotic-free LB, culture at 37°C, 250 rpm, and stop when OD600 reaches 0.4-0.6. Prepare electroporation competent cells on ice;
[0289] 2) Add 2.5 μL of the pKD46-Bxb1 plasmid obtained in step 3.4 of Example 3 to the competent cells and resuspend them. After mixing evenly, take 70 μL of the resuspended cells and transfer them to an electroporation cuvette for electroporation transformation;
[0290] 3) Add 1 mL of antibody-free LB to the electroporation cup to resuspend the cells, transfer to a centrifuge tube and culture at 30°C, 250 rpm for 1 hour to obtain the culture solution;
[0291] 4) Apply 100 μL of the culture solution on an LB agar plate with ampicillin and culture overnight at 30°C for about 16 hours;
[0292] 5) Inoculate a single colony on the overnight LB agar plate into 5 mL of ampicillin-resistant LB, add 0.1 M L-arabinose for induction, and culture for 6-8 hours to obtain a bacterial solution;
[0293] 6) Take 10 μL of bacterial solution and streak it on an ampicillin-resistant LB agar plate and culture it overnight at 30°C for about 16 hours;
[0294] 7) Select 9 single colonies on the agar plate and resuspend them in 10 μL of antibiotic-free LB. Use a pipette tip to drop 1 μL of the bacterial solution on the plates with kanamycin and ampicillin respectively. After the bacterial solution is dried, incubate at 30°C overnight. Finally, select the colonies that grow on the ampicillin plate but not on the kanamycin plate to obtain a strain that does not contain exogenous plasmid kanamycin resistance and replication origin in the genome.
[0295] Among them, agarose was purchased from Yisheng Biotechnology (Shanghai) Co., Ltd., product number 10208ES60; the solution for preparing the gel was 1X TAE solution, including 40mM tris (hydroxymethylaminomethane) (Tris), 20mM acetic acid, 1mM disodium ethylenediaminetetraacetate (EDTA), pH 8.0.
[0296] 5.6. Circular Integration
[0297] Subsequently, the attB 3 site and the pKD46-PhiC31 plasmid can be used to continue integrating the exogenous gene into the genome, so that the exogenous gene can be circularly integrated into the genome, thereby realizing the stacking storage of the exogenous gene on the genome.
[0298] Here, attB / P 3 refers to attB / P(PhiC31).
[0299] Among them, the use of attB 3 site to achieve the integration of exogenous genes into the genome requires the construction of a new vector plasmid pYF24. The partial structure is: pKD4 (vector) -attP 3-biofix (prefix) -CcdB-ColEⅠ-biofix (suffix) -attB 1-attP2-KanR-attB 2. The construction process is consistent with pYF23.
[0300] 23 single colonies were randomly selected from the agar plate of the strain without exogenous plasmid kanamycin resistance and replication origin in the genome in step 5.3. Three parallel experiments were set up to perform colony agarose gel PCR and calculate the integration efficiency. PCR results are shown in Figure 4 The integration efficiency results are shown in Figure 5 .
[0301] Integration efficiency: number of colonies with the correct band / total number of colonies.
[0302] from Figure 5 It can be seen that the integration efficiency of the exogenous gene into the genome using the method of the present application is 86.95%.
[0303] Comparative Example
[0304] In this comparative example, sfGFP was integrated into the E. coli genome using conventional methods.
[0305] In the conventional method, the vector plasmid used is consistent with pYF23 / 24 except that it does not contain CcdB-ColEⅠ. When the exogenous gene is to be integrated into the genome with the help of the vector plasmid, the following steps are required: 1) First, the linear fragments of the vector plasmid and the exogenous gene sfGFP are obtained by PCR amplification; 2) The recombinant product is obtained by homologous recombination kit and transformed into DH5αλpir competent cells. Since there is no screening of the toxic protein CcdB gene, false positives will appear in the colonies on the agar plate after transformation; 3) In order to screen the correctly recombined plasmid, colony PCR is required and sent to Sanger sequencing; 4) The correctly sequenced plasmid is extracted; 5) The recombinant plasmid is then transformed into MG1655 containing attB (TP901-1) to finally achieve the genomic integration of the exogenous gene.
[0306] Comparison between conventional methods and this method
[0307] Schematic diagram of the process of the conventional method and this method, comparing the differences between the conventional method and this method in terms of operation process and working time, demonstrating the superiority of this method
[0308] Figure 6 The right side of the figure shows a schematic flow chart of the conventional method for constructing a plasmid and integrating the foreign plasmid into the genome.
[0309] The origin of replication of the vector plasmid is R6K, so that it can only replicate when the pir gene is present. The donor plasmid containing the exogenous target gene carries ampicillin resistance. The above plasmids are used as templates to obtain PCR products. After recombination by the recombination kit, there are basically four situations in the recombinant products: target gene fragments that have not been recombined, the remaining vector plasmids in the recombination system, the donor plasmid template, and the correctly recombined product. Due to the screening of the plate with resistance after transformation, only the colonies with the same resistance as the correct recombinant product can grow, so the colonies on the plate may carry the vector plasmid and the correctly recombined plasmid. In order to select the correct recombinant plasmid, subsequent colony PCR and Sanger sequencing verification are required. After the plasmid is extracted and transformed into Escherichia coli MG1655 carrying the integration site and serine recombinase, the colonies with the exogenous gene genome integrated can be obtained on the plate. The whole process is complicated and cumbersome to operate, and the time cost is high.
[0310] Figure 6 The right side of the middle diagram is a schematic diagram of the process of the present application for constructing a plasmid and integrating an exogenous plasmid into the genome.
[0311] A toxic protein gene CcdB and a replication origin ColEⅠ were inserted in the middle of the vector plasmid pYF23 or pYF24. The Escherichia coli MG1655 strain expressing CcdB could not grow normally. In the correct recombinant product, the CcdB gene was replaced by the exogenous target gene. Therefore, the nucleic acid construct containing the CcdB-ColEⅠ sequence would not affect subsequent experiments.
[0312] The linear fragments of the vector plasmid and the exogenous gene sfGFP were obtained by PCR amplification, and the recombinant product was obtained by a homologous recombination kit. The recombinant product was directly transformed into Escherichia coli MG1655 carrying the integration site and serine recombinase. After plating, Escherichia coli colonies with the exogenous gene integrated into the genome were obtained.
[0313] The nucleic acid construct of the present application comprises a CcdB-ColEⅠ fragment, and different exogenous genes are subsequently inserted. The integration of the exogenous target gene can be achieved by recombination between the first recognition sequence and the corresponding integration site in the host cell, thus avoiding tedious screening steps, saving time, and having high application value.
[0314] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limitations of the present invention. In addition, the various modifications listed herein and the variations of methods and compositions in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications obvious to those skilled in the art as described above to obtain the invention should be included within the scope of the present invention.
Claims
1. A nucleic acid construct, characterized in that It contains CcdB-ColEⅠ sequence, and also contains attB sequence or attP sequence of the first site-specific recombinase, attB sequence or attP sequence of the second site-specific recombinase, and attB sequence and attP sequence of the third site-specific recombinase.
2. The nucleic acid construct according to claim 1, wherein Include at least one of the following technical features: A1) the site-specific recombinase is selected from serine recombinase; preferably, the serine recombinase is selected from one or more of TP901-1, Bxb1 and PhiC31; more preferably, the recognition sequence of TP901-1 is selected from attP 1 sequence and attB 1 sequence, the recognition sequence of Bxb1 is selected from attP 2 sequence and attB 2 sequence, and the recognition sequence of PhiC31 is selected from attP 3 sequence and attB 3 sequence; A2) The CcdB-ColEⅠ sequence is from 5 ’ End to 3 ’ The ends contain CcdB and ColEⅠ in sequence; A3) the nucleic acid construct sequentially contains the attB sequence or attP sequence of the first site-specific recombinase, the CcdB-ColEⅠ sequence, the attB sequence or attP sequence of the second site-specific recombinase, and the attB sequence and attP sequence of the third site-specific recombinase, wherein the first site-specific recombinase and the second site-specific recombinase cannot be attB sequences or attP sequences at the same time; A4) The nucleic acid construct further comprises a selection marker gene, wherein the selection marker gene is located between the attB sequence and the attP sequence of the third site-specific recombinase; preferably, the selection marker is a resistance gene.
3. The nucleic acid construct according to claim 2, wherein Include at least one of the following technical features: B1) the attP sequence of the first site-specific recombinase and the attP sequence of the third site-specific recombinase are each independently selected from attP 1 sequence, attP 2 sequence, and attP 3 sequence; B2) the attB sequence of the second site-specific recombinase and the attB sequence of the third site-specific recombinase are each independently selected from attB 1 sequence, attB 2 sequence, and attB 3 sequence.
4. The nucleic acid construct according to claim 2, wherein The attB 1 sequence includes the sequence shown in SEQ ID NO.1; And / or, the attB 2 sequence includes the sequence shown in SEQ ID NO.2; And / or, the attB 3 sequence includes the sequence shown in SEQ ID NO.3; And / or, the attP 1 sequence includes the sequence shown in SEQ ID NO.4; And / or, the attP 2 sequence includes the sequence shown in SEQ ID NO.5; And / or, the attP 3 sequence includes the sequence shown in SEQ ID NO.6; And / or, the CcdB sequence includes the sequence shown in SEQ ID NO.7; And / or, the ColEⅠ sequence includes the sequence shown in SEQ ID NO.
8.
5. The nucleic acid construct according to claim 2, wherein The nucleic acid construct contains attP 1 sequence, CcdB-ColEⅠ sequence, attB 3 sequence, attP 2 sequence, selection marker gene and attB 2 sequence in sequence; and / or, the nucleic acid construct contains attP 3 sequence, CcdB-ColEⅠ sequence, attB 1 sequence, attP 2 sequence, selection marker gene and attB 2 sequence in sequence; And / or, homology arms for homologous recombination are provided at both ends of the CcdB-ColEⅠ sequence.
6. The nucleic acid construct according to claim 1, wherein The backbone of the nucleic acid construct is selected from pKD4.
7. The nucleic acid construct according to claim 5, wherein The sequence of the nucleic acid construct is shown in SEQ ID NO.9 or SEQ ID NO.
10.
8. A recombination system, characterized in that The recombination system comprises a vector plasmid, a plasmid expressing a first site-specific recombinase and / or a plasmid expressing a second site-specific recombinase, and a plasmid expressing a third site-specific recombinase, wherein the vector plasmid is a nucleic acid construct as described in any one of claims 1 to 7; optionally, it also comprises a donor plasmid, and the donor plasmid comprises a target gene.
9. The recombination system according to claim 8, characterized in that The recombination system contains at least two different vector plasmids to facilitate the circular integration of foreign genes into the genome.
10. A recombinant cell, characterized in that The recombinant vector carrying the target gene is obtained by introducing a plasmid for specific recombination of the expression site into a host cell, wherein the recombinant vector carrying the target gene is obtained by recombination of a vector plasmid and the target gene in the recombination system as described in claim 8.
11. Use of the nucleic acid construct according to any one of claims 1 to 7 or the recombination system according to claim 8 for genome integration, gene recombination or gene editing.
12. A method for genome integration, gene recombination or gene editing, characterized in that: The target gene is recombined with the nucleic acid construct according to any one of claims 1 to 7 to obtain a recombinant vector, and genome integration, gene recombination or gene editing is performed under the action of a site-specific recombinase.
13. The method according to claim 12, characterized in that The following steps are involved: 1) Recombining the target gene with the nucleic acid construct according to any one of claims 1 to 7 to obtain a recombinant vector; 2) transferring the recombinant vector and the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase into the host cell to complete genome recombination; 3) Transform the plasmid expressing the three-site specific recombinase into the host cell to remove the foreign resistance; Optionally, also include: 4) Cyclic steps 1) to 3) are used to recombine multiple target genes into the host cell genome respectively, wherein the plasmid expressing the first site-specific recombinase or the plasmid expressing the second site-specific recombinase is used alternately in each cycle.
